Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP

Soranobu Ninomiya, Takeshi Hara, Hisashi Tsurumi, Masato Hoshi, Nobuhiro Kanemura, Naoe Goto, Senji Kasahara, Masahito Shimizu, Hiroyasu Ito, Kuniaki Saito, Yoshinobu Hirose, Tetsuya Yamada, Takeshi Takahashi, Mitsuru Seishima, Tsuyoshi Takami, Hisataka Moriwaki

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Indoleamine 2,3-dioxygenase (IDO) exerts immunomodulatory effects due to enzymatic activities catalyzing the essential amino acid L-tryptophan. IDO activity might play an important role in regulating immune responses exerted by antigen-presenting cells as a potent tool to help escape from assault by the immune system. In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Not only the lymphoma cells themselves but also dendritic cells (DCs) expressed IDO. Positive IDO expression in lymphoma cells was found in 38 cases (32%). Complete remission rates in patients with IDO-positive DLBCL and IDO-negative DLBCL were 55.3% and 79.0% (p=0.008), while 3-year overall survival rates were 49.8% and 78.8%, respectively (p=0.0003). IDO activity might thus play an important role in DLBCL and cells that express IDO appear important for determining outcomes after R-CHOP treatment. IDO might represent a candidate therapeutic target for DLBCL patients who show resistance to chemotherapy.

Original languageEnglish
Pages (from-to)409-416
Number of pages8
JournalAnnals of Hematology
Volume90
Issue number4
DOIs
Publication statusPublished - 01-04-2011
Externally publishedYes

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Lymphoma, Large B-Cell, Diffuse
Neoplasms
Lymphoma
Essential Amino Acids
Histocompatibility Antigens Class II
Vincristine
Antigen-Presenting Cells
Prednisone
Tryptophan
Doxorubicin
Cyclophosphamide
Dendritic Cells
Immune System
Therapeutics
Survival Rate

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Ninomiya, Soranobu ; Hara, Takeshi ; Tsurumi, Hisashi ; Hoshi, Masato ; Kanemura, Nobuhiro ; Goto, Naoe ; Kasahara, Senji ; Shimizu, Masahito ; Ito, Hiroyasu ; Saito, Kuniaki ; Hirose, Yoshinobu ; Yamada, Tetsuya ; Takahashi, Takeshi ; Seishima, Mitsuru ; Takami, Tsuyoshi ; Moriwaki, Hisataka. / Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. In: Annals of Hematology. 2011 ; Vol. 90, No. 4. pp. 409-416.
@article{7ec6cdcfcdc746b58720163a67ab7ad1,
title = "Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP",
abstract = "Indoleamine 2,3-dioxygenase (IDO) exerts immunomodulatory effects due to enzymatic activities catalyzing the essential amino acid L-tryptophan. IDO activity might play an important role in regulating immune responses exerted by antigen-presenting cells as a potent tool to help escape from assault by the immune system. In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Not only the lymphoma cells themselves but also dendritic cells (DCs) expressed IDO. Positive IDO expression in lymphoma cells was found in 38 cases (32{\%}). Complete remission rates in patients with IDO-positive DLBCL and IDO-negative DLBCL were 55.3{\%} and 79.0{\%} (p=0.008), while 3-year overall survival rates were 49.8{\%} and 78.8{\%}, respectively (p=0.0003). IDO activity might thus play an important role in DLBCL and cells that express IDO appear important for determining outcomes after R-CHOP treatment. IDO might represent a candidate therapeutic target for DLBCL patients who show resistance to chemotherapy.",
author = "Soranobu Ninomiya and Takeshi Hara and Hisashi Tsurumi and Masato Hoshi and Nobuhiro Kanemura and Naoe Goto and Senji Kasahara and Masahito Shimizu and Hiroyasu Ito and Kuniaki Saito and Yoshinobu Hirose and Tetsuya Yamada and Takeshi Takahashi and Mitsuru Seishima and Tsuyoshi Takami and Hisataka Moriwaki",
year = "2011",
month = "4",
day = "1",
doi = "10.1007/s00277-010-1093-z",
language = "English",
volume = "90",
pages = "409--416",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "4",

}

Ninomiya, S, Hara, T, Tsurumi, H, Hoshi, M, Kanemura, N, Goto, N, Kasahara, S, Shimizu, M, Ito, H, Saito, K, Hirose, Y, Yamada, T, Takahashi, T, Seishima, M, Takami, T & Moriwaki, H 2011, 'Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP', Annals of Hematology, vol. 90, no. 4, pp. 409-416. https://doi.org/10.1007/s00277-010-1093-z

Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. / Ninomiya, Soranobu; Hara, Takeshi; Tsurumi, Hisashi; Hoshi, Masato; Kanemura, Nobuhiro; Goto, Naoe; Kasahara, Senji; Shimizu, Masahito; Ito, Hiroyasu; Saito, Kuniaki; Hirose, Yoshinobu; Yamada, Tetsuya; Takahashi, Takeshi; Seishima, Mitsuru; Takami, Tsuyoshi; Moriwaki, Hisataka.

In: Annals of Hematology, Vol. 90, No. 4, 01.04.2011, p. 409-416.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP

AU - Ninomiya, Soranobu

AU - Hara, Takeshi

AU - Tsurumi, Hisashi

AU - Hoshi, Masato

AU - Kanemura, Nobuhiro

AU - Goto, Naoe

AU - Kasahara, Senji

AU - Shimizu, Masahito

AU - Ito, Hiroyasu

AU - Saito, Kuniaki

AU - Hirose, Yoshinobu

AU - Yamada, Tetsuya

AU - Takahashi, Takeshi

AU - Seishima, Mitsuru

AU - Takami, Tsuyoshi

AU - Moriwaki, Hisataka

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Indoleamine 2,3-dioxygenase (IDO) exerts immunomodulatory effects due to enzymatic activities catalyzing the essential amino acid L-tryptophan. IDO activity might play an important role in regulating immune responses exerted by antigen-presenting cells as a potent tool to help escape from assault by the immune system. In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Not only the lymphoma cells themselves but also dendritic cells (DCs) expressed IDO. Positive IDO expression in lymphoma cells was found in 38 cases (32%). Complete remission rates in patients with IDO-positive DLBCL and IDO-negative DLBCL were 55.3% and 79.0% (p=0.008), while 3-year overall survival rates were 49.8% and 78.8%, respectively (p=0.0003). IDO activity might thus play an important role in DLBCL and cells that express IDO appear important for determining outcomes after R-CHOP treatment. IDO might represent a candidate therapeutic target for DLBCL patients who show resistance to chemotherapy.

AB - Indoleamine 2,3-dioxygenase (IDO) exerts immunomodulatory effects due to enzymatic activities catalyzing the essential amino acid L-tryptophan. IDO activity might play an important role in regulating immune responses exerted by antigen-presenting cells as a potent tool to help escape from assault by the immune system. In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Not only the lymphoma cells themselves but also dendritic cells (DCs) expressed IDO. Positive IDO expression in lymphoma cells was found in 38 cases (32%). Complete remission rates in patients with IDO-positive DLBCL and IDO-negative DLBCL were 55.3% and 79.0% (p=0.008), while 3-year overall survival rates were 49.8% and 78.8%, respectively (p=0.0003). IDO activity might thus play an important role in DLBCL and cells that express IDO appear important for determining outcomes after R-CHOP treatment. IDO might represent a candidate therapeutic target for DLBCL patients who show resistance to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=79955928670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955928670&partnerID=8YFLogxK

U2 - 10.1007/s00277-010-1093-z

DO - 10.1007/s00277-010-1093-z

M3 - Article

VL - 90

SP - 409

EP - 416

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 4

ER -